OTLK Wins FDA Appeal, Plans BLA Resubmission in June 2026 for ONS-5010/LYTENAVA™ with Anticipated Class 1 Resubmission and PDUFA Date within 60 Days
Outlook Therapeutics, Inc. Common Stock · Now $0.73
+76% in 3d after detection
Post-detection moves
1h
+15%
1d
+41%
3d
+76%
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS